“PIK3CA Mutations in ERBB2/HER2-Positive Early Breast Cancer Linked to Lower Response Rates and Worse Survival”

https://pubmed.ncbi.nlm.nih.gov/38117494

PIK3CA mutations in ERBB2/HER2-positive early breast cancer are associated with lower pathologic complete response rates and worse long-term event-free survival, particularly in hormone receptor-positive and luminal subtypes.